Researchers led by the University of Edinburgh have made an important discovery that could change the way Crohn's disease is treated, as they were able to identify the mechanism that leads to the formation of scar tissue in the intestines, medically known as "fibrosis".
This fibrosis occurs when groups of immune cells within the intestine stimulate neighboring cells to produce large amounts of collagen, leading to hardening and narrowing of the intestinal wall, and may even result in a complete obstruction requiring surgical intervention.
The significance of this discovery lies in the fact that fibrosis is one of the most difficult complications of Crohn's disease to treat, because current medications only focus on combating inflammation and do not address the scarring itself. Therefore, understanding the mechanism linking immune activity to collagen production opens the door to developing future drugs capable of effectively preventing fibrosis or slowing its progression.
To arrive at these results, the research team analyzed intestinal tissue samples from Crohn's patients suffering from fibrosis, focusing on the "ileum," the end of the small intestine where the disease most commonly appears.
The researchers noted significant fibrosis and a marked accumulation of immune cells in the patients' tissues compared to healthy tissues, especially in the submucosa, which may play an early role in the development of fibrosis.
The researchers then used a sophisticated technique known as single-cell RNA sequencing to study gene activity within individual cells. They discovered signaling interactions between three main cell groups: immune cells called Crohn's lymphoid aggregates, endothelial cells that line blood vessels, and collagen-producing cells. The endothelial cells were also shown to form distinct structures surrounding immune cells, suggesting that they actively contribute to the progression of fibrosis.
Commenting on these results, Dr. Shahida Dean, a consultant gastroenterologist at Lothian Health and a lecturer at the University of Edinburgh, explained that fibrosis remains one of the most challenging complications of Crohn's disease because current treatments target inflammation rather than scarring itself, adding that understanding cellular signaling pathways will help in developing new treatments that prevent fibrosis or slow its progression.
For his part, Dr. Michael Glinka, a researcher at the University of Edinburgh, confirmed that combining traditional pathology with modern technologies has revealed previously unknown biological pathways and could provide promising new drug targets.
The scientific journal The Journal of Pathology published this research, conducted in collaboration between researchers and clinicians from across the UK, with support from the Leona M. and Harry P. Helmsley charity. Catherine Winsor of Crohn's and Collets UK commented that this early research is very exciting because it offers real hope for treating not only the inflammation but also the permanent damage caused by Crohn's disease.
It is worth noting that surgery remains the only option for treating fibrosis, because after each operation to remove the affected part of the intestine, the disease gradually recurs and scar tissue forms again, leading to recurrent obstruction. However, this new scientific breakthrough offers hope for the development of future treatments that directly target fibrosis, potentially eliminating the need for repeated surgeries and significantly improving patients' quality of life.
